Evidence for a role for dopamine D3 receptors in the effects of dopamine agonists on operant behaviour in rats

Behavioural Pharmacology

Volumn 7, Issue 5, 1996, Pages 477-482

  Sanger, D J ^a   Depoortere, R ^a   Perrault, G ^a  

^a SANOFI   (France)

Author keywords

Dopamine agonist; Dopamine D3 receptors; Operant behaviour

Indexed keywords

2 DIPROPYLAMINO 7 HYDROXYTETRALIN; 3,4,4A,10B TETRAHYDRO 4 PROPYL 2H,5H [1]BENZOPYRANO[4,3 B][1,4]OXAZIN 9 OL; AMISULPRIDE; APOMORPHINE; BENZAMIDE DERIVATIVE; BROMOCRIPTINE; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; HALOPERIDOL; NEUROLEPTIC AGENT; PRECLAMOL; PRESYNAPTIC RECEPTOR; QUINELORANE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CORRELATION FUNCTION; DRUG ANTAGONISM; DRUG MECHANISM; DRUG SELECTIVITY; GENETIC TRANSFECTION; INSTRUMENTAL CONDITIONING; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MITOGENESIS; NONHUMAN; RAT; RECEPTOR AFFINITY; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0029965634     PISSN: 09558810     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Acri JB, Carter SR, Ailing K, Geter-Douglass B, Dijkstra D, Wikstrom H, Katz JL and Witkin JM (1995) Assessment of cocaine-like discriminative stimulus effects of dopamine D3 receptor ligands. European Journal of Pharmacology, 281, R7-R9.
2. Bouthenet ML, Souil E, Martres MP, Sokoloff P, Giros B and Schwartz JC (1991) Localization of dopamine D3 receptor mRNA in the rat brain using in situ hybridization histochemistry: comparison with dopamine D2 receptor mRNA. Brain Research, 564, 203-219.
3. Boyer P, Lecrubier Y, Puech AJ, Dewailly J and Aubin F (1995) Treatment of negative symptoms in schizophrenia with amisulpride. British Journal of Psychiatry, 166, 68-72.
4. Bristow LJ, Cook GP, Gay JC, Kulagoswski JJ, Landon L, Murray F, Saywell KL, Young L and Hutson PH (1996) The behavioural and neurochemical profile of the putative dopamine D3 receptor agonist (+)-PD 128907, in the rat. Neuropharmacology, 35, 285-294.
5. Bums KD, Pacheco MA, Filtz TM, Kung MP, Kung HF and Molinoff PB (1995) Lack of discrimination by agonists for D2 and D3 dopamine receptors. Neuropsychopharmacology, 12, 335-345.
6. Caine SB and Koob GF (1993) Modulation of cocaine self-administration in the rat through D-3 dopamine receptors. Science, 260, 1814-1816.
7. Carnoy P, Ravard S, Wemerman B, Soubrie Ph and Simon P (1986) Behavioral deficits induced by low doses of apomorphine in rats: evidence for a motivational and cognitive dysfunction which discriminates among neuroleptic drugs. Pharmacology, Biochemistry and Behavior, 25, 503-509.
8. Delcker A, Schoon ML, Oczkowski B and Gaertner HJ (1990) Amisulpride versus haloperidol in treatment of schizophrenic patients. Results of a double-blind study. Pharmacopsychiatry, 23, 125-130.
9. Depoortere R, Perrault Gh and Sanger DJ (1996) Behavioural effects in the rat of the putative dopamine D3 receptor agonist 7-OH-DPAT: comparison with quinpirole and apomorphine. Psychopharmacology, 124, 231-240.
10. Di Chiara G, Porceddu ML, Vargin L, Argiolas and Gessa GL (1976) Evidence for dopamine receptors mediating sedation in the mouse brain. Nature, 264, 564-567.
11. Gilbert DB and Cooper SJ (1995) 7-OH-DPAT injected into the accumbens reduces locomotion and sucrose ingestion: D3 autoreceptor-mediated effects? Pharmacology, Biochemistry and Behavior, 52, 275-280.
12. Griffon N, Diaz J, Levesque D, Sautel F, Schwartz JC, Sokoloff P, Simon P, Constentin J, Garrido F, Mann A and Wermuth C (1995) Localization, regulation, and role of the dopamine D-3 receptor are distinct from those of the D-2 receptor. Clinical Neuropharmacology, 18, S130-S142.
13. Kreiss DS, Bergstrom DA, Gonzalez AM, Huang KX, Sibley DR and Walters JR (1995) Dopamine receptor agonist potencies for inhibition of cell firing correlate with dopamine D3 receptor binding affinities. European Journal of Pharmacology, 277, 209-214.
14. 3H)hydroxy-N, N-di-n-propyl-2-aminotetralin. Proceedings of the National Academy of Sciences USA, 89, 8155-8159.
15. Malmberg AH, Jackson DM, Eriksson AM and Mohell NA (1993) Unique binding characteristics of antipsychotic agents interacting with human dopamine D2A, D2B and D3 receptors. Molecular Pharmacology, 43, 749-754.
16. McElroy J, Zeller K, Amy K, Ward K, Crawley J, Mazzola A, Keim W and Rohrbach K (1993) In vivo agonist properties of 7-hydroxy-N,N-di-N-propyl-2-aminotetralin, a dopamine D3-selective receptor ligand. Drug Development Research, 30, 257-259.
17. Meador-Woodruff J (1995) Neuroanatomy of dopamine receptor gene expression: potential substrates for neuropsychiatric illness. Clinical Neuropharmacology, 18, 514-524.
18. Millan MJ, Peglion JL, Vian J, Rivet JM, Brocco M, Gobert A, Newman-Tancredi A, Dacquet C, Bervoets K, Girardon S, Jacques V, Chaput C and Audinot V (1995) Functional correlates of dopamine D3 receptor activation in the rat in vivo and their modulation by the selective antagonist, (+)-S 14297: 1. Activation of postsynaptic D3 receptors mediates hypothermia, whereas blockade of D2 receptors elicits prolactin secretion and catalepsy. Journal of Pharmacology and Experimental Therapeutics, 275, 885-898.
19. Mohell N, Sallemark M, Rosqvist S, Malmberg A, Hogberg T and Jackson DM (1993) Binding characteristics of remoxipride and its metabolites to dopamine D2 and D3 receptors. European Journal of Pharmacology, 238, 121-125.
20. Pugsley TA, Davis MD, Akunne HC, Mackenzie RG, Shih YH, Damsma G, Wikstrom H, Whetzel SZ, Georgic LM, Cooke LW, Demattos SB, Corbin AE, Glase SA, Wise LD, Dijkstra D and Heffner TG (1995) Neurochemical and functional characterization of the preferentially selective dopamine D3 agonist PD 128907. Journal of Pharmacology and Experimental Therapeutics, 275, 1355-1366.
21. Sanger DJ and Perrault G (1995) Effects of typical and atypical antipsychotic drugs on response decrement patterns in rats. Journal of Pharmacology and Experimental Therapeutics, 272, 708-713.
22. Sautel F, Griffon N, Levesque D, Pilon C, Schwartz JC and Sokoloff P (1995) A functional test identifies dopamine agonists selective for D3 versus D2 receptors. Neuroreport, 6, 329-332.
23. Scatton B, Perrault G, Gonon F, Depoortere R, Sanger D and Schoemaker H (1995) Novel neuroleptics acting on presynaptic dopaminergic receptors. European Neuropsychopharmacology, 5, S19.
24. Schwartz JC, Griffon N, Diaz J, Levesque D, Sautel F, Sokoloff P, Simon P, Costentin J, Garrido F, Mann A and Wermuth (1995) The D3 receptor and its relevance in psychiatry. International Clinical Psychopharmacology, 10, Suppl 3, 15-20.
25. 3H]7-OH-DPAT labels both dopamine D3 receptors and σ sites in the bovine caudate nucleus. European Journal of Pharmacology, 242, R1-R2.
26. Sokoloff P, Giros B, Martres MP, Bouthenet ML and Schwartz JC (1990) Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature, 347, 146-151.
27. Sokoloff P, Andrieux M, Besancon R, Pilon C, Martres PM, Giros B and Schwartz JC (1992a) Pharmacology of human dopamine D3 receptor expressed in a mammalian cell line: comparison with D2 receptor. European Journal of Pharmacology, Molecular Pharmacology Section, 225, 331-337.
28. Sokoloff P, Giros B, Martres MP, Andrieux M, Besancon R, Pilon C, Bouthenet ML, Souil E and Schwartz JC (1992b) Localization and function of the D3 dopamine receptor. Arzneimittelforschung, 42, 224-230.
29. Stahle L (1992) Do autoreceptors mediate dopamine agonist-induced yawning and suppression of exploration? A critical review. Psychopharmacology, 106, 1-13.
30. Stahle L and Ungerstedt U (1986) Effect of neuroleptic drugs on apomorphine induced inhibition of exploratory behaviour in the rat: implication for the identity of dopamine receptors. Pharmacology, Biochemistry and Behavior, 25, 473-480.
31. Stahle L, Ljungberg T, Rodebjer A, Ogren SO and Ungerstedt U (1987) Differential effects of the dopamine antagonist remoxipride on apomorphine induced behaviour in the rat. Pharmacology and Toxicology, 60, 227-232.
32. Starr MS and Starr BS (1995) Motor actions of 7-OH-DPAT in normal and reserpine-treated mice suggest involvement of both dopamine D2 and D3 receptors. European Journal of Pharmacology, 277, 151-158.
33. Svensson K, Carlsson A and Waters N (1994) Locomotor inhibition by the D3 ligand R-(+)-7-OH-DPAT is independent of changes in dopamine release. Journal of Neural Transmission. General Section, 95, 71-74.
34. Waters N, Svensson K, Haadsma-Svensson SR, Smith MW and Carlsson A (1993) The dopamine D3-receptor: a postsynaptic receptor inhibitory on rat locomotor activity. Journal of Neural Transmission. General Section, 94, 11-19.